A Crossover Study Evaluating 3 Non-medicated Silicone IVRs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-20

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of this study is to assess different external diameters of intravaginal rings (IVRs) for adherence, preference, and acceptability. To assess these domains, women in male-partnered relationships will use three different size IVRs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA

NCT07039591

Contraceptive Usage

RECRUITING EARLY_PHASE1

A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method

NCT00469170

HIV Infections

COMPLETED EARLY_PHASE1

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

NCT01755741

Human Immunodeficiency Virus

COMPLETED PHASE1

Safety and Adherence of a Non-medicated Intravaginal Ring (IVR)

NCT01268332

Healthy

COMPLETED PHASE2

Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings

NCT06163274

Safety Acceptability

TERMINATED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total. Each couple will participate for approximately 4 months, including screening. After providing written informed consent at screening, females and their male partners will be evaluated against the inclusion and exclusion criteria by providing their medical, contraceptive, and sexual history as well as undergoing a clinical exam. The exam will include a visual inspection of the genitalia (men) and a speculum exam (women). Potential participants will be recruited by Emory University (Atlanta, GA) and Einstein College of Medicine (Bronx, NY) by contacting prior research participants who've consented to be contacted for new studies; advertising; and distribution of flyers in the study communities. All recruitment materials will be approved by the relevant IRBs prior to use. After screening, women will have an additional 4 visits and their male partners will have 1 additional in-person visit for enrollment and 3 remote visits. Before and after using each IVR, women will have a pelvic exam. If women report symptoms during interim visits, they will have a pelvic exam and will restart IVR use based on the clinical judgement of the site investigator. After enrollment, men who report symptoms possibly related to IVR use will be asked to attend the clinic for an examination. Follow-up visits (in-person for women and remote for men) will include counseling on protocol adherence, contraception, HIV risk reduction counseling. Women will be shown how to use the IVR at Visit 1/Enrollment and will be able to practice ring insertion and removal at that first visit. At monthly visits, women will be examined to check that the IVR is in place.

ADHERENCE: The primary adherence measure will be assessed via daily SMS text messages to women in which they will report if the IVR was out of the vagina in the previous 24h and if so, for how long. At monthly visits, women will respond to a computer assisted self-interview (CASI) questionnaire asking them to rate their adherence in terms of how well they feel they adhered to the IVR instructions for use. They will also be asked to report in more detail about expulsions and removals and the context in which those happen; feeling the ring during daily activities and during sex; and any symptoms experienced in the previous month.

PREFERENCE: We will ask women and their male partners to choose the IVR they think they will prefer at baseline -- before using any IVRs -- and then ask them to state their preference after using all 3 IVRs. Preferences at baseline and endline, and between males and females within each couple, will be compared.

ACCEPTABILITY: Acceptability will be assessed via the monthly CASI interviews according to an adapted version of the Merkatz et al IVR acceptability model.

SAFETY: Safety will be assessed by recording AEs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hiv Pregnancy Related

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

We propose a randomized, open-label, parallel group, 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 couples. At enrollment, each woman will be randomly assigned to 1 of 6 sequences of IVR use (A-B-C, A-C-B, etc.) and will use each of the 3 IVRs (A, B and C) for 30d per IVR (90d total).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silicone IVR 46mm external diameter

Non-medicated 46 mm ring.

Group Type EXPERIMENTAL

Impact of ring size on adherence

Intervention Type DEVICE

The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.

Silicone IVR 56mm external diameter

Non-medicated 56mm ring.

Group Type EXPERIMENTAL

Impact of ring size on adherence

Intervention Type DEVICE

The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.

Silicone IVR 66mm external diameter

Non-medicated 66mm ring.

Group Type EXPERIMENTAL

Impact of ring size on adherence

Intervention Type DEVICE

The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Impact of ring size on adherence

The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Females:

* Aged 18-40 years old, inclusive, at Screening based on self-report
* Sexually active, defined as having had penile-vaginal sex with a male partner at least four times per month (e.g. once a week), on average, in the three months before Screening
* In a mutually monogamous relationship with the same male partner for at least 6 months prior to Screening, based on self-report
* Male partner is eligible and consents to participation
* Healthy based on medical history and physical exam at Screening
* Currently using effective non-vaginal contraception for at least 3 months prior to screening, including injectable, oral contraception, contraceptive patch or sterilization (male or female) based on self-report
* HIV-negative per test at Screening
* Not pregnant per urine pregnancy test at Screening and Enrollment
* Negative for chlamydia, gonorrhea, trichomoniasis or urinary tract infection (UTI) at screening
* Symptomatic vulvovaginal candidiasis or bacterial vaginosis (BV) at Screening. (Participants who test positive at initial screening may be treated and rescreened after completing treatment).
* Competent to provide written informed consent based on Investigator's assessment
* Owns or has access to Smart phone per self-report
* Agrees to not participate in any other clinical research for the duration of this trial

Males:

* Aged at least 18 years old at Screening based on self-report
* Sexually active, defined as having had penile-vaginal sex with a female partner at least four times per month (e.g. once a week), on average, in the three months before Screening
* In a mutually monogamous relationship with the same female partner for at least 6 months prior to Screening, based on self-report
* Female partner is eligible and consents to participation
* Healthy based on medical history and physical exam, including visual inspection of genitalia at Screening
* HIV-negative per test at Screening
* Negative for chlamydia, gonorrhea, trichomoniasis per tests at Screening (per local standard of care) at Screening
* Competent to provide written informed consent based on investigator's assessment
* Owns or has access to a Smart phone, per self-report
* Agrees to not participate in any other clinical research for the duration of this trial

Exclusion Criteria

Females:

* Known or suspected allergy to silicone, as reported by participant
* Positive pregnancy test at Screening or Enrollment based on urine hCG test
* Positive for HIV per test at Screening
* Presence of any clinically significant genital epithelial findings (e.g. abrasions, ulcerations, lacerations, or vesicles) suspicious of STIs at Screening or Enrollment
* Positive chlamydia, gonorrhea, or trichomoniasis test at Screening (or Enrollment)
* Current urinary complaints or diagnosed UTI at Screening (or Enrollment)
* Presence of genital abnormalities via visual exam with speculum that would contraindicate IVR use at Screening or Enrollment
* Significant uterine or vaginal prolapse, or urethral obstruction
* Recurrent vaginitis (three or more episodes within the prior year)
* Unexplained vaginal bleeding per self-report within the 3 months before Screening
* Currently breastfeeding per self-report
* Partial or complete hysterectomy per self-report
* Gynecological surgery in the 6 months prior to Screening per self-report
* Within 6 weeks post abortion or 6 months postpartum, per Self-report.
* Using vaginal contraception (diaphragm, female condom, spermicide, IVR)
* Abnormal finding on examination or a social or medical condition which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data.
* Any other condition the clinician feels would jeopardize the health and wellbeing of the participant after assessing the participant's potential eligibility for the study
* Unable to comply with study requirements, including but not limited to, attending all study visits and using the IVRs as directed.
* Currently participating in any other clinical research trial involving investigational or marketed products

Males:

* Known or suspected allergy to silicone, as reported by
* Positive test for HIV at Screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes